posted on 2023-04-03, 21:41authored byChristopher W. Murray, Jennifer J. Brady, Min K. Tsai, Chuan Li, Ian P. Winters, Rui Tang, Laura Andrejka, Rosanna K. Ma, Christian A. Kunder, Pauline Chu, Monte M. Winslow
Summary of GSEA analysis on Sik-targeted tumors using gene sets from previous publications centered on transcriptional profiling of the Lkb1-deficient state.
Funding
NIH
Damon Runyon Cancer Research Foundation
TRDRP
History
ARTICLE ABSTRACT
The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood. To investigate the tumor-suppressive capacity of four canonical families of LKB1 substrates in vivo, we used CRISPR/Cas9-mediated combinatorial genome editing in a mouse model of oncogenic KRAS-driven lung adenocarcinoma. We demonstrate that members of the SIK family are critical for constraining tumor development. Histologic and gene-expression similarities between LKB1- and SIK-deficient tumors suggest that SIKs and LKB1 operate within the same axis. Furthermore, a gene-expression signature reflecting SIK deficiency is enriched in LKB1-mutant human lung adenocarcinomas and is regulated by LKB1 in human cancer cell lines. Together, these findings reveal a key LKB1–SIK tumor-suppressive axis and underscore the need to redirect efforts to elucidate the mechanisms through which LKB1 mediates tumor suppression.
Uncovering the effectors of frequently altered tumor suppressor genes is critical for understanding the fundamental driving forces of cancer growth. Our identification of the SIK family of kinases as effectors of LKB1-mediated tumor suppression will refocus future mechanistic studies and may lead to new avenues for genotype-specific therapeutic interventions.This article is highlighted in the In This Issue feature, p. 1469